Axa Sells 270 Shares of C.R. Bard, Inc. (BCR)
Axa decreased its position in shares of C.R. Bard, Inc. (NYSE:BCR) by 0.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 50,749 shares of the medical instruments supplier’s stock after selling 270 shares during the quarter. Axa owned approximately 0.07% of C.R. Bard worth $16,265,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds have also recently made changes to their positions in BCR. Farallon Capital Management LLC purchased a new stake in C.R. Bard in the 2nd quarter valued at about $463,101,000. Renaissance Technologies LLC raised its holdings in C.R. Bard by 35.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,295,600 shares of the medical instruments supplier’s stock valued at $409,552,000 after buying an additional 338,900 shares during the period. Alpine Associates Management Inc. raised its holdings in C.R. Bard by 10.0% in the 3rd quarter. Alpine Associates Management Inc. now owns 924,263 shares of the medical instruments supplier’s stock valued at $296,226,000 after buying an additional 83,851 shares during the period. Wells Fargo & Company MN raised its holdings in C.R. Bard by 32.8% in the 3rd quarter. Wells Fargo & Company MN now owns 775,683 shares of the medical instruments supplier’s stock valued at $248,607,000 after buying an additional 191,443 shares during the period. Finally, Westchester Capital Management LLC raised its holdings in C.R. Bard by 14.6% in the 3rd quarter. Westchester Capital Management LLC now owns 575,106 shares of the medical instruments supplier’s stock valued at $184,321,000 after buying an additional 73,478 shares during the period. 79.11% of the stock is currently owned by hedge funds and other institutional investors.
Shares of C.R. Bard, Inc. (NYSE BCR) opened at $333.81 on Tuesday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.37 and a current ratio of 1.72. The stock has a market cap of $24,382.50, a PE ratio of 28.89, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52. C.R. Bard, Inc. has a one year low of $218.72 and a one year high of $337.73.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 8th will be paid a dividend of $0.26 per share. The ex-dividend date is Thursday, December 7th. This represents a $1.04 dividend on an annualized basis and a yield of 0.31%. C.R. Bard’s dividend payout ratio (DPR) is presently 13.70%.
In related news, insider Jim C. Beasley sold 3,395 shares of the company’s stock in a transaction that occurred on Thursday, December 14th. The shares were sold at an average price of $332.00, for a total transaction of $1,127,140.00. Following the sale, the insider now directly owns 25,630 shares in the company, valued at $8,509,160. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Betty D. Larson sold 5,906 shares of the company’s stock in a transaction that occurred on Friday, October 20th. The stock was sold at an average price of $330.16, for a total transaction of $1,949,924.96. Following the sale, the vice president now owns 10,753 shares in the company, valued at $3,550,210.48. The disclosure for this sale can be found here. Insiders have sold 210,032 shares of company stock worth $68,777,261 over the last quarter. Insiders own 0.80% of the company’s stock.
BCR has been the topic of several research analyst reports. Cowen restated a “hold” rating and issued a $317.00 price objective on shares of C.R. Bard in a report on Friday, November 3rd. Needham & Company LLC restated a “hold” rating on shares of C.R. Bard in a report on Thursday, October 26th. Jefferies Group restated a “hold” rating and issued a $317.00 price objective on shares of C.R. Bard in a report on Thursday, September 14th. Barclays boosted their price objective on shares of C.R. Bard from $245.00 to $337.00 and gave the company an “equal weight” rating in a report on Monday, November 6th. Finally, ValuEngine lowered shares of C.R. Bard from a “buy” rating to a “hold” rating in a report on Friday, December 1st. One analyst has rated the stock with a sell rating, nine have issued a hold rating and one has issued a strong buy rating to the company. C.R. Bard has a consensus rating of “Hold” and an average price target of $303.50.
ILLEGAL ACTIVITY WARNING: “Axa Sells 270 Shares of C.R. Bard, Inc. (BCR)” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.watchlistnews.com/axa-sells-270-shares-of-c-r-bard-inc-bcr/1772872.html.
C.R. Bard Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).
Receive News & Ratings for C.R. Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard and related companies with MarketBeat.com's FREE daily email newsletter.